Multi-Center, Double-Masked, Randomized, Placebo-Controlled Phase 2b Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Having Undergone Cataract Surgery With Implantation of a Posterior Chamber Intraocular Lens (IOL)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Dexamethasone (Primary)
- Indications Ocular inflammation; Postoperative pain
- Focus Therapeutic Use
- Sponsors EyeGate Pharma
- 09 Nov 2017 According to an EyeGate Pharma media release, topline data is expected to be released in the first quarter of 2018.
- 08 Nov 2017 Status changed from recruiting to active, no longer recruiting, according to an EyeGate Pharma media release.
- 01 Aug 2017 According to an EyeGate Pharma media release, first patient has been enrolled.